Andra AP fonden increased its stake in Amgen, Inc. (NASDAQ:AMGN) by 13.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,500 shares of the medical research company’s stock after acquiring an additional 7,000 shares during the period. Amgen makes up about 0.3% of Andra AP fonden’s holdings, making the stock its 15th largest holding. Andra AP fonden’s holdings in Amgen were worth $11,919,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Kwmg LLC acquired a new stake in shares of Amgen in the second quarter valued at $108,000. Mainstay Capital Management LLC ADV acquired a new stake in shares of Amgen in the second quarter valued at $111,000. Braun Bostich & Associates Inc. acquired a new stake in shares of Amgen in the first quarter valued at $113,000. WealthTrust Fairport LLC acquired a new stake in shares of Amgen in the first quarter valued at $121,000. Finally, Gables Capital Management Inc. acquired a new stake in shares of Amgen in the first quarter valued at $174,000. Institutional investors and hedge funds own 82.48% of the company’s stock.
Several analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their price objective on Amgen from $191.00 to $192.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 11th. Jefferies Financial Group restated a “buy” rating and issued a $200.00 price target on shares of Amgen in a research note on Monday, July 16th. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $207.00 price target on the stock in a research note on Tuesday, June 26th. Finally, Morgan Stanley raised their price target on Amgen from $210.00 to $212.00 and gave the company an “overweight” rating in a research note on Thursday, October 11th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the company. Amgen presently has a consensus rating of “Hold” and a consensus target price of $204.90.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.52 by $0.31. The company had revenue of $6.06 billion for the quarter, compared to analyst estimates of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the company posted $3.27 earnings per share. As a group, analysts anticipate that Amgen, Inc. will post 13.96 earnings per share for the current fiscal year.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: Marijuana Stocks Investing Considerations
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.